2-(10-chloro-6-methyl-5-oxo-2,6,9,11-tetraazabicyclo[5.4.0]undecane-7,9,11-trien-2-yl)ethanenitrile | 1001346-67-3

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 嘧啶二氮卓类
• 英文名称: 2-(10-chloro-6-methyl-5-oxo-2,6,9,11-tetraazabicyclo[5.4.0]undecane-7,9,11-trien-2-yl)ethanenitrile
• 英文别名: 2-(10-chloro-6-methyl-5-oxo-2,6,9,11-tetraazabicyclo[5.4.0]undeca-7,9,11-trien-2-yl)acetonitrile；2-(10-chloro-6-methyl-5-oxo-2,6,9,11-tetrazabicyclo[5.4.0]undeca-7,9,11-trien-2-yl)acetonitrile；2-(10-Chloro-6-methyl-5-oxo-2,6,9,11-tetrazabicyclo[5.4.0]undeca-7,9,11-trien-2-yl)acetonitrile；2-(2-chloro-5-methyl-6-oxo-7,8-dihydropyrimido[4,5-b][1,4]diazepin-9-yl)acetonitrile
• CAS: 1001346-67-3
• 化学式: C₁₀H₁₀ClN₅O
• 分子量: 251.675
• InChiKey: GEMMLXGNDZXMAD-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  0.5
• 重原子数：
  17
• 可旋转键数：
  1
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.4
• 拓扑面积：
  73.1
• 氢给体数：
  0
• 氢受体数：
  5

反应信息

• 作为反应物：
  描述：

  2-(10-chloro-6-methyl-5-oxo-2,6,9,11-tetraazabicyclo[5.4.0]undecane-7,9,11-trien-2-yl)ethanenitrile 、 4-氨基-3-甲氧基-N-(1-甲基哌啶-4-基)苯甲酰胺 、 对甲苯磺酸一水合物 在 甲醇 、 ammonia methanol 、 resultant material 作用下， 以 4-甲基-2-戊醇 、 水 、 甲醇 、 异丙醇 为溶剂， 反应 24.33h， 以to yield the title compound as a light brown solid (21 mg, 9%)的产率得到3-methoxy-4-[[6-methyl-2-[(4-methylpentan-2-yloxycarbonimidoyl)methyl]-5-oxo-2,6,9,11-tetrazabicyclo[5.4.0]undeca-7,9,11-trien-10-yl]amino]-N-(1-methyl-4-piperidyl)benzamide
  参考文献：
  名称：

  NOVEL COMPOUNDS

  摘要：

  提供了一个公式(I)的化合物，其制造过程，制药组合物及其在治疗中的用途。

  公开号：

  US20080009482A1
• 作为产物：
  描述：

  在 tris-(dibenzylideneacetone)dipalladium(0) 、 sodium hydride 、 caesium carbonate 、 4,5-双二苯基膦-9,9-二甲基氧杂蒽 、 三氟乙酸 作用下， 以 1,4-二氧六环 、 二氯甲烷 、 N,N-二甲基乙酰胺 、 mineral oil 为溶剂， 反应 7.5h， 生成 2-(10-chloro-6-methyl-5-oxo-2,6,9,11-tetraazabicyclo[5.4.0]undecane-7,9,11-trien-2-yl)ethanenitrile
  参考文献：
  名称：

  A novel approach to functionalised 5,7,8,9-tetrahydropyrimido[4,5-b][1,4]diazepin-6-ones using intramolecular palladium-catalysed amidation

  摘要：

  The development of a novel palladium-catalysed amidation approach towards 5,7,8,9-tetrahydropyrimido[4,5-b][1,4]diazepin-6-one templates is highlighted. The route proceeds through the reaction of an amino amide, generated by 1,4-addition of an amine to an acrylamide, with 5-bromo-2,4-dichloropyrimidine and final palladium-catalysed cyclisation to provide the functionalised scaffold in up to 60% isolated yield over three steps. The route offers efficiency advantages over the previously reported nitro-reduction cyclisation approach to these molecules. It also provides alternative means to introduce bulky alkyl substituents at the amide nitrogen. The application of this route in the synthesis of a variety of analogues is described. (C) 2012 Published by Elsevier Ltd.

  DOI：

  10.1016/j.tetlet.2012.03.125

文献信息

• NOVEL COMPOUNDS
  申请人：HALSALL Christopher Thomas

  公开号：US20080009482A1

  公开（公告）日：2008-01-10

  There is provided a compound of formula (I): processes for the manufacture thereof, pharmaceutical compositions thereof and uses in therapy.

  提供了一个化合物的化学式(I)： 其制备方法，药物组合物以及在治疗中的用途。
• US7709471B2
  申请人：——

  公开号：US7709471B2

  公开（公告）日：2010-05-04
• A novel approach to functionalised 5,7,8,9-tetrahydropyrimido[4,5-b][1,4]diazepin-6-ones using intramolecular palladium-catalysed amidation
  作者：Gregory R. Carr、James L. Feron、Paul D. Johnson、Craig A. Roberts、David A. Rudge、Iain Simpson、Gail L. Wrigley

  DOI：10.1016/j.tetlet.2012.03.125

  日期：2012.9

  The development of a novel palladium-catalysed amidation approach towards 5,7,8,9-tetrahydropyrimido[4,5-b][1,4]diazepin-6-one templates is highlighted. The route proceeds through the reaction of an amino amide, generated by 1,4-addition of an amine to an acrylamide, with 5-bromo-2,4-dichloropyrimidine and final palladium-catalysed cyclisation to provide the functionalised scaffold in up to 60% isolated yield over three steps. The route offers efficiency advantages over the previously reported nitro-reduction cyclisation approach to these molecules. It also provides alternative means to introduce bulky alkyl substituents at the amide nitrogen. The application of this route in the synthesis of a variety of analogues is described. (C) 2012 Published by Elsevier Ltd.
• Compounds
  申请人：AstraZeneca AB

  公开号：US07709471B2

  公开（公告）日：2010-05-04

  There is provided a compound of formula (I): processes for the manufacture thereof, pharmaceutical compositions thereof and uses in therapy.

  提供了一个公式（I）的化合物：其制造过程，制药组合物及其在治疗中的用途。